Lipid nanoparticles for intranasal administration: application to nose-to-brain delivery

References

• Blasi P, Glovagnoli S, Schoubben A, et al. Solid lipid nanoparticles for targeted brain drug delivery. Adv Drug Deliv Rev. 2007;59:454–477.
   PubMed Web of Science ®Google Scholar
• Patel M, Souto EB, Singh KK. Advances in brain drug targeting and delivery: limitations and challenges of solid lipid nanoparticles. Expert Opin Drug Deliv. 2013;10:889–905.
   PubMed Web of Science ®Google Scholar
• Gastaldi L, Battaglia L, Peira E, et al. Solid lipid nanoparticles as vehicles of drugs to the brain: current state of the art. Eur J Pharm Biopharm. 2014;87:433–444.
   PubMed Web of Science ®Google Scholar
• Shadab M, Gulam M, Sanjula B, et al. Nanoneurotherapeutics approach intended for direct nose to brain delivery. Drug Dev Ind Pharm. 1922–34;41:2015.
   Google Scholar
• Nutt JG, Burchiel KJ, Comella CL, et al. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology. 2003;60:69–73.
   PubMed Web of Science ®Google Scholar
• Mistry A, Stolnik S, Illum L. Nanoparticles for direct nose-to-brain delivery of drugs. Int J Pharm. 2009;379:146–157.
   PubMed Web of Science ®Google Scholar
• Mittal D, Ali A, Md S, et al. Insights into direct nose to brain delivery: current status and future perspective. Drug Deliv. 2014;21:75–86.
   PubMed Web of Science ®Google Scholar
• Dhuria SV, Hanson LR, Frey WH. Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharm Sci. 2010;99:1654–1673.
   PubMed Web of Science ®Google Scholar
• Djupesland PG, Messina JC, Mahmoud RA. The nasal approach to delivering treatment for brain diseases: an anatomic, physiologic, and deliverytechnology overview, Ther. Deliv. 2014;5:709–733.
   PubMedGoogle Scholar
• Lochhead JJ, Thorne RG. Intranasal delivery of biologics to the centralnervous system. Adv Drug Deliv Rev. 2012;64:614–628.
   PubMed Web of Science ®Google Scholar
• Johanson C, Johanson N. Merging transport data for choroid plexus with blood-brain barrier to model CNS homeostasis and disease more effectively. CNS Neurol Disord Drug Targets. 2016;15:1151–1180.
   PubMed Web of Science ®Google Scholar
• Sood S, Jain K, Gowthamarajan K. Intranasal therapeutic strategies for management of Alzheimer’s disease. J Drug Target. 2014;22:279–294.
   PubMed Web of Science ®Google Scholar
• Kulkarni AD, Vanjari YH, Sancheti KH, et al. Nanotechnology-mediated nose to brain drug delivery for Parkinson’s disease: a mini review. J Drug Target. 2015;23:775–788.
   PubMed Web of Science ®Google Scholar
• Rejman J, Oberle V, Zuhorn IS, et al. Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis. Biochem J. 2004;377:159–169.
   PubMed Web of Science ®Google Scholar
• Lauzon MA, Daviaua A, Marcos B, et al. Nanoparticle-mediated growth factor delivery systems: a new way to treat Alzheimer’s disease. J Control Release. 2015;206:187–205.
   PubMed Web of Science ®Google Scholar
• Haffejee N, Du Plessis J, Muller DG, et al. Intranasal toxicity of selected absorption enhancers. Pharmazie. 2001;56:882–888.
   PubMed Web of Science ®Google Scholar
• Van Woensel M, Wauthoz N, Rosière R, et al. Formulations for intranasal delivery of pharmacological agents to combat brain disease: a new opportunity to tackle GBM? Cancers. 2013;5:1020–1048.
   PubMedGoogle Scholar
• Mehnert W, Mäder K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev. 2001;47:165–196.
   PubMed Web of Science ®Google Scholar
• Battaglia L, Gallarate M. Lipid nanoparticles: state of the art, new preparation methods and challenges in drug delivery. Expert Opin Drug Deliv. 2012; 9:497–508.
   PubMed Web of Science ®Google Scholar
• Jafek BW. Ultrastructure of human nasal mucosa. Laryngoscope. 1983;93:1576–1599.
   PubMed Web of Science ®Google Scholar
• Ruszniak C, Devalia JL, Lozewicz S, et al. The assessment of nasal mucociliary clearance and the effect of drugs. Respir Med. 1994;88:89–101.
   PubMed Web of Science ®Google Scholar
• Rassu G, Cossu M, Langasco R, et al. Propolis as lipid bioactive nano-carrier for topical nasal drug delivery. Coll Surf B: Biointerf. 2015;136:908–917.
   PubMed Web of Science ®Google Scholar
• Aboud HM, El Komy MH, Ali AA, et al. Development, optimization, and evaluation of carvedilol-loaded solid lipid nanoparticles for intranasal drug delivery. AAPS PharmSciTech. 2016;17:1–13.
   PubMed Web of Science ®Google Scholar
• Reichel A. The role of blood-brain barrier studies in the pharmaceutical industry. Curr Drug Metab. 2006;7:183–203.
   PubMed Web of Science ®Google Scholar
• Pardeshi CV, Belgamwar VS, Tekade AR, et al. Novel surface modified polymer-lipid hybrid nanoparticles as intranasal carriers for ropinirole hydrochloride: in vitro, ex vivo and in vivo pharmacodynamic evaluation. J Mater Sci Mater Med. 2013;24:2101–2115.
   PubMed Web of Science ®Google Scholar
• Shah B, Khunt D, Bhatt H, et al. Application of quality by design approach for intranasal delivery of rivastigmine loaded solid lipid nanoparticles: effect on formulation and characterization parameters. Eur J Pharm Sci. 2015;78:54–66.
   PubMed Web of Science ®Google Scholar
• Chandra Bhatt P, Srivastava P, Pandey P, et al. Nose to brain delivery of astaxanthin-loaded solid lipid nanoparticles: fabrication, radio labeling, optimization and biological studies. RSC Adv. 2016;6:10001–10010.
   Web of Science ®Google Scholar
• Muntimadugu E, Dhommati R, Jain A, et al. Intranasal delivery of nanoparticle encapsulated tarenflurbil: a potential brain targeting strategy for Alzheimer’s disease. Eur J Pharm Sci. 2016;92:224–234.
   PubMed Web of Science ®Google Scholar
• Rassu G, Soddu E, Posadino AM. Nose-to-brain delivery of BACE1 siRNA loaded in solid lipid nanoparticles for Alzheimer’s therapy. Colloid Surf B: Biointerfaces. 2017;152:296–301.
   PubMed Web of Science ®Google Scholar
• Bhatt R, Singh D, Prakash A, et al. Development, characterization and nasal delivery of rosmarinic acid-loaded solid lipid nanoparticles for the effective management of huntington’s disease. Drug Deliv. 2015;22:931–939.
   PubMed Web of Science ®Google Scholar
• Esposito E, Cortesi R, Drechsler M, et al. Nanoformulations for dimethyl fumarate: physicochemical characterization and in vitro/in vivo behavior. Eur J Pharm Biopharm. 2017;115:285–296.
   PubMed Web of Science ®Google Scholar
• Patel S, Chavhan S, Soni H, et al. Brain targeting of risperidone-loaded solid lipid nanoparticles by intranasal route. J Drug Target. 2011;19:468–474.
   PubMed Web of Science ®Google Scholar
• Fatouh AM, Elshafeey AH, Abdelbary A. Agomelatine-based in situ gels for brain targeting via the nasal route: statistical optimization, in vitro, and in vivo evaluation. Drug Deliv. 2017;24:1077–1085.
   PubMed Web of Science ®Google Scholar
• Fatouh AM, Elshafeey AH, Abdelbary A. Intranasal agomelatine solid lipid nanoparticles to enhance brain delivery: formulation, optimization and in vivo pharmacokinetics. Drug Des Devel Ther. 1815-25;2017:11.
   Google Scholar
• Singh AP, Saraf SK, Saraf SA. SLN approach for nose-to-brain delivery of alprazolam. Drug Deliv Transl Res. 2012;2:498–507.
   PubMed Web of Science ®Google Scholar
• Eskandari S, Varshosaz J, Minaiyan M, et al. Brain delivery of valproic acid via intranasal administration of nanostructured lipid carriers: in vivo pharmacodynamic studies using rat electroshock model. Int J Nanomedicine. 2011;6:363–371.
   PubMedGoogle Scholar
• Morsi NM, Ghorab DM, Badie HA. Bioadhesive brain targeted nasal delivery of an ant ischemic drug. Pharma Res. 2013;8:43–61.
   Google Scholar
• Joshi AS, Patel HS, Belgamwar VS, et al. Solid lipid nanoparticles of ondansetron Hcl for intranasal delivery: development, optimization and evaluation. J Mater Sci Mater Med. 2012;23:2163–2175.
   PubMed Web of Science ®Google Scholar
• Kumar M, Kakkar V, Mishra AK, et al. Intranasal delivery of streptomycin sulfate (strs) loaded solid lipid nanoparticles to brain and blood. Int J Pharm. 2014;461:223–233.
   PubMed Web of Science ®Google Scholar
• Gupta S, Kesarla R, Chotai N, et al. Systematic approach for the formulation and optimization of solid lipid nanoparticles of efavirenz by high pressure homogenization using design of experiments for brain targeting and enhanced bioavailability. Biomed Res Int. 2017;5984014.
   PubMed Web of Science ®Google Scholar
• Troy DB, Beringer P. The science and practice of pharmacy. Remington: Lippincott Williams & Wilkins Editors; 2006.
   Google Scholar
• U.S. Department of Health and Human Services Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER). Guidance for industry nasal spray and inhalation solution, suspension, and spray drug products – chemistry, manufacturing, and controls. Documentation. July 2002
   Google Scholar
• Illum L. Nasal drug delivery: new developments and strategies. Drug Discov Today. 2002;7:1184–1189.
   PubMed Web of Science ®Google Scholar
• Illum L. Nasal drug delivery – recent developments and future prospects. J Control Rel. 2012;161:254–263.
   PubMed Web of Science ®Google Scholar